CTOs on the Move

Glendale Adventist Medical Center

www.glendaleadventist.com

 
The purpose of the Healthcare Foundation is to support the work and mission of Glendale Adventist Medical Center through philanthropy. Foundation responsibilities include the receipt and disbursement of all gifts to the Medical Center, as well as the
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Palm Medical Centers

Founded in 2013, Palm Medical Centers is a provider of value-based, capitated primary care services with a focus on high-quality clinical outcomes, cost-effective care, and a patient-centric experience. Operating a network of 19 medical centers across five counties in Florida, PMC serves more than 34,000 Medicare Advantage and managed Medicaid patients. Partnering with numerous managed care organizations, Palm Medical Centers offers comprehensive and integrated medical care to plan members with a focus on quality. In addition to primary care services, the company coordinates cardiology, dentistry, optometry, pediatrics, podiatry, psychiatry and other specialist services. Palm Medical Centers continues to seek partnership opportunities with high quality providers in existing and new markets.

TechHealth

TechHealth is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Carolina Medical Group Managers (NCMGM)

North Carolina Medical Group Managers (NCMGM) is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Society of Pain Educators

American Society of Pain Educators is a Montclair, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.